BETHESDA, Md., Feb. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at two upcoming investor conferences; one sponsored by the Biotechnology Industry Organization (BIO) and the other by Roth Capital Partners.
Dr. Itin will present at the 2008 BIO CEO and Investor Conference in New York, on Wednesday, February 13, 2008 at 2:00 pm Eastern Time (8:00 pm Central European Time). An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com, as well as a replay and download of the presentation slides following the event.
Dr. Itin will also present at the Roth Capital Partners 2008 OC Growth Stock Conference in Dana Point California, on Tuesday, February 19, 2008 at 9:30 am Pacific Time.
About Micromet, Inc. (http://www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation and
autoimmune diseases. Three of its antibodies are in clinical development.
MT103 (MEDI-538), the most advanced antibody in Micromet's product pipeline
developed using the BiTE(R) antibody technology platform , is being
developed in a phase 2 clinical trial for the treatment of patients with
acute lymphoblastic leukemia, and in a phase 1 clinical trial for the
treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies
represent a new class of antibodies that activate a patient's own cytotoxic
T cells to eliminate cancer cells. Micromet is developing MT103 in
collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The
|SOURCE Micromet, Inc.|
Copyright©2008 PR Newswire.
All rights reserved